1Wise RA,Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease:an assessment of current therapies[J].American Journal of Medicine,2007,(8 suppl 1):S4-S13.
2Pauwels R,Joos GF,Fogarty C. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD[J].Pulmonary Pharmacology and Therapeutics,2008,(02):385-392.
3Bleecker ER,Emmett A,Crater G. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD:Response by beta-agonist reversibility[J].Pulmonary Pharmacology and Therapeutics,2008,(04):682-688.
4Niewoehner DE,Lapidus R,Cote C. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease[J].Pulmonary Pharmacology and Therapeutics,2009,(06):587-592.
5Agoram BM,Milligan PA,Graaf PH. A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data:Application to inhaled bronchodilators[J].European Journal of Pharmaceutical Sciences,2008,(4-5):250-256.
6Simoni-Wastila L,Blanchette CM,Qian J. Burden of chronic obstructive pulmonary disease in medicare beneficiaries residing in long-term care facilities[J].American Journal of Geriatric Pharmacotherapy,2009,(05):262-270.
7Cazzola M,Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD[J].Pulm Pharmacol Tber,2010.257-267.
6Clark SC. Lung injury after cardiopulmonary bypass [J]. Perfusion,2006(21):225-228.
7Guizilini S, Gomes WJ, Faresin SM, et al. Influence of Pleurotomy on Pulmonary function after Off-Pump Coronary Artery Bypass Grafting [J]. Ann Thorac Surg, 2007 (84):817-822.
